Plexin-B2 and Semaphorins Do Not Drive Rhabdomyosarcoma Proliferation or Migration

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Rhabdomyosarcoma (RMS) is a common pediatric soft tissue sarcoma with poor outcomes for metastatic or recurrent disease.
• Novel therapeutic strategies are needed to improve survival rates in RMS patients.
• The Plexin-Semaphorin pathway is an emerging target in pediatric sarcoma research.

Purpose of the Study:

• To investigate the expression of Plexin-B2 and SEMA4C ligands in RMS tumors and cell models.
• To assess the role of Plexin-B2 in RMS cell growth and migration using RNA interference.
• To explore the potential of the Plexin-Semaphorin pathway as a therapeutic target in RMS.

Main Methods:

• Analysis of Plexin-B2 and SEMA4C protein expression in clinical RMS samples and cell lines.
• RNA interference (RNAi) to knockdown Plexin-B2 expression in alveolar and embryonal RMS cell models.
• Assessment of cell growth and migration assays following Plexin-B2 knockdown.

Main Results:

• Plexin-B2 expression was confirmed across human RMS samples, with varied expression of its subunits and identification of preferred Semaphorin ligands.
• Plexin-B2 knockdown demonstrated context-dependent effects on RMS cell growth.
• Selective inhibition of cell migration was observed after Plexin-B2 knockdown, independent of expression levels.

Conclusions:

• Plexin-B2 and its SEMA4C ligands play a context-specific role in RMS.
• Findings suggest a potential patient-specific (stochastic) role for this pathway in RMS pathogenesis.
• Further research into the Plexin-Semaphorin pathway may reveal novel therapeutic strategies for RMS.